候选LC-MS参考方法用于定量心脏标志物1-32 B型利钠肽
研究建立并验证了基于LC-MS的候选参考方法,用于定量血浆中B型利钠肽(BNP),并在临床相关浓度15-150 fmol/g范围内评估。该方法应用于UK NEQAS心脏标志物计划样本,结果显示参考方法结果持续低于免疫测定,且免疫测定间存在差异。该方法有潜力支持外部质量评估、理解测定偏倚并建立BNP参考测量程序。
要点
- 建立了LC-MS候选参考方法,可定量血浆BNP在15-150 fmol/g范围。
- 参考方法结果持续低于免疫测定,且免疫测定间存在差异。
- 该方法有潜力支持EQA、理解测定偏倚并建立BNP参考测量程序。
核心结论
- LC-MS候选参考方法可用于BNP定量,有潜力支持外部质量评估、理解免疫测定偏倚并建立参考测量程序。
研究设计与样本
- 研究开发并验证了基于蛋白沉淀、固相萃取和LC-MS的BNP定量方法,线性范围为15-150 fmol/g。
- BNP初级校准品通过氨基酸分析和胰蛋白酶消化溯源至国际单位制。
主要发现
- 参考方法结果持续低于免疫测定结果。
- 不同免疫测定之间观察到差异,证实了先前数据。
关键数值与推荐
- 方法定量范围为15-150 fmol/g。
- 免疫测定结果差异可达45%。
临床怎么用
- 该方法有潜力用于支持外部质量评估计划。
- 有助于理解免疫测定偏倚并建立BNP参考测量程序。
- 该方法有潜力多重检测循环中截短形式的BNP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: B-type natriuretic peptide (BNP) is a 32 amino acid cardiac hormone routinely measured by immunoassays to diagnose heart failure. While it is reported that immunoassay results can vary up to 45%, no attempt of standardization and/or harmonization through the development of certified reference materials (CRMs) or reference measurement procedures (RMPs) has yet been carried out. METHODS: B-type natriuretic peptide primary calibrator was quantified traceably to the International System of Units (SI) by both amino acid analysis and tryptic digestion. A method for the stabilization of BNP in plasma followed by protein precipitation, solid phase extraction (SPE) and liquid chromatography (LC) mass spectrometry (MS) was then developed and validated for the quantification of BNP at clinically relevant concentrations (15-150 fmol/g). RESULTS: The candidate reference method was applied to the quantification of BNP in a number of samples from the UK NEQAS Cardiac Markers Scheme to demonstrate its applicability to generate reference values and to preliminary evaluate the commutability of a potential CRM. The results from the reference method were consistently lower than the immunoassay results and discrepancy between the immunoassays was observed confirming previous data. CONCLUSIONS: The application of the liquid chromatography-mass spectrometry (LC-MS) method to the UK NEQAS samples and the correlation of the results with the immunoassay results shows the potential of the method to support external quality assessment schemes, to improve understanding of the bias of the assays and to establish RMPs for BNP measurements. Furthermore, the method has the potential to be multiplexed for monitoring circulating truncated forms of BNP.
引用
- Torma AF, Groves K, Biesenbruch S, et al. A candidate liquid chromatography mass spectrometry reference method for the quantification of the cardiac marker 1-32 B-type natriuretic peptide. Clin Chem Lab Med. 2017. PMID: 28426429. doi:10.1515/cclm-2016-1054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。